Sarepta Therapeutics Inc (SRPT)

120.86 -2.03 (-1.65%) USD  |  NASDAQ  |  Jan 30, 16:00
120.87 +0.01 (+0.01%) After-Hours: 20:00
More

Sarepta Therapeutics News

News

Headline
Wire
Time (ET)
Global drug spending to reach $1.9T by 2027 – IQVIA
SA Breaking News
01/22 12:00
7 Biotech Stocks That Will Make You Rich in 10 Years
Yahoo
01/18 15:44
--RBC Cuts Price Target on Sarepta Therapeutics to $195 From $204, Maintains Outperform Rating
MT Newswires
01/13 08:08
FDA clinical holds pick up amid race for risky, innovative medicines – WSJ
SA Breaking News
01/10 09:45
Credit Suisse Raises Sarepta Therapeutics' Price Target to $114 From $101, Keeps Neutral Rating
MT Newswires
01/10 08:00
Needham Adjusts Price Target on Sarepta Therapeutics to $160 From $158, Maintains Buy Rating
MT Newswires
01/10 07:35
Sarepta Therapeutics expects 32% net product revenue growth in Q4
SA Breaking News
01/09 17:35
Sarepta Therapeutics Reports Preliminary Q4, Full-Year 2022 Net Product Revenue Jump
MT Newswires
01/09 15:29
Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2022 Net Product Revenues
Globe Newswire
01/09 13:28
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Is Expected To Breakeven In The Near Future
Yahoo
01/08 08:39
2 Under-the-Radar Biotech Stocks to Buy in 2023
Yahoo
01/06 08:45
Catalent, Sarepta Therapeutics Sign Manufacturing Deal for Gene Therapy Candidate
MT Newswires
01/05 10:27
Sarepta and Catalent Expand Strategic Manufacturing Partnership With Commercial Supply Agreement for Duchenne Muscular Dystrophy Gene Therapy Candidate
Yahoo
01/05 08:30
Sarepta Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
Globe Newswire
01/03 08:30
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire
12/30 17:58
BTIG Adjusts Sarepta Therapeutics' Price Target to $160 From $125, Keeps Buy Rating
MT Newswires
12/22 09:29
UBS Upgrades Sarepta Therapeutics to Buy From Neutral, Adjusts Price Target to $158 From $100
MT Newswires
12/16 11:52
2 Top Healthcare Stocks to Buy for the Long Haul
Yahoo
12/09 09:53
Sarepta Therapeutics (SRPT) Up 17.1% Since Last Earnings Report: Can It Continue?
Yahoo
12/02 11:31
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Yahoo
11/30 18:00
Sarepta's (SRPT) DMD Gene Therapy BLA Gets FDA Priority Review
Yahoo
11/29 12:07
Sarepta Surges As It Nears The Finish Line With A Muscular Dystrophy Gene Therapy
Yahoo
11/28 16:12
Catalent spikes as Barclays says FDA cleared Form 483 reports
SA Breaking News
11/28 14:40
Thinking about trading options or stock in Axsome Therapeutics, Sarepta Therapeutics, Las Vegas Sands, Apple, or Microsoft?
PR Newswire
11/28 09:31
Sector Update: Health Care Stocks Decline Premarket Monday
MT Newswires
11/28 09:25
Sarepta expected to get FDA decision on Duchenne treatment by May 29
Yahoo
11/28 08:50
Sarepta Says Its Application to Expedite Approval of Duchenne Muscular Dystrophy Treatment Secured US FDA Acceptance
MT Newswires
11/28 07:49
Sarepta/Roche gene therapy for Duchenne gets FDA priority review
SA Breaking News
11/28 07:43
Sarepta Therapeutics Announces That U.S. FDA has Accepted for Filing and Granted Priority Review for the Biologics License Application for SRP-9001, Sarepta’s Gene Therapy for the Treatment of Ambulant Individuals with Duchenne Muscular Dystrophy
Yahoo
11/28 07:00
Sarepta Therapeutics to Present at the Evercore ISI HealthCONx Conference
Globe Newswire
11/23 08:30
--UBS Adjusts Sarepta Therapeutics Price Target to $100 From $94, Maintains Neutral Rating
MT Newswires
11/04 12:36
Sarepta (SRPT) Q3 Loss Wider-Than-Expected, Sales Lag Estimates
Yahoo
11/03 13:25
--Needham Adjusts Price Target on Sarepta Therapeutics to $158 From $162, Maintains Buy Rating
MT Newswires
11/03 12:39
--Credit Suisse Adjusts Sarepta Therapeutics' Price Target to $101 From $93, Keeps Neutral Rating
MT Newswires
11/03 11:07
--RBC Cuts Price Target on Sarepta Therapeutics to $190 From $193, Maintains Outperform Rating
MT Newswires
11/03 08:35
Dow Jones Futures Fall: Market Rally Reeling As Fed's Powell Signals Higher Peak Rate
Yahoo
11/03 08:12
--Berenberg Bank Adjusts Sarepta Therapeutics Price Target to $108 From $98, Maintains Hold Rating
MT Newswires
11/03 08:04
Sarepta Therapeutics (SRPT) Q3 2022 Earnings Call Transcript
Yahoo
11/03 02:00
Sarepta Therapeutics (SRPT) Reports Q3 Loss, Lags Revenue Estimates
Yahoo
11/02 18:25
-- Earnings Flash (SRPT) SAREPTA THERAPEUTICS Posts Q3 Revenue $230.3M, vs. Street Est of $234.6M
MT Newswires
11/02 16:19
-- Earnings Flash (SRPT) SAREPTA THERAPEUTICS Posts Q3 Loss $-0.80, vs. Street Est of $-0.74
MT Newswires
11/02 16:19
Sarepta Therapeutics Announces Third Quarter 2022 Financial Results and Recent Corporate Developments
Globe Newswire
11/02 16:05
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire
10/31 18:00
Sarepta Therapeutics to Announce Third Quarter 2022 Financial Results
Globe Newswire
10/26 08:30
SVB Securities Adjusts Sarepta Therapeutics' Price Target to $145 from $126, Maintains Outperform Rating
MT Newswires
10/17 08:25
Morgan Stanley Adjusts Price Target on Sarepta Therapeutics to $141 From $135, Maintains Equalweight Rating
MT Newswires
10/13 09:36
Sarepta Therapeutics Presents New Data from its Gene Therapy and RNA Platforms at World Muscle Society 2022
Globe Newswire
10/07 08:30
--RBC Raises Price Target on Sarepta Therapeutics to $193 From $182, Maintains Outperform Rating
MT Newswires
10/06 07:42
Sarepta Therapeutics Seeks FDA Accelerated Approval for SRP-9001
MT Newswires
09/29 11:31
Sarepta Therapeutics Submits Biologics License Application for SRP-9001 for the Treatment of Ambulant Patients with Duchenne Muscular Dystrophy
Globe Newswire
09/29 08:30
Insider Buy: Sarepta Therapeutics
MT Newswires
09/15 09:54
Sarepta Therapeutics Prices Offering of $1 Billion of Convertible Notes
MT Newswires
09/14 08:03
Sarepta Therapeutics Prices $1.0 Billion of Convertible Senior Notes Due 2027
Globe Newswire
09/14 07:00
Sarepta Therapeutics Plans $1 Billion Convertible Notes Offering; Shares Fall After Hours
MT Newswires
09/12 16:50
Sarepta Therapeutics Announces Proposed Offering of $1.0 Billion of Convertible Senior Notes Due 2027
Globe Newswire
09/12 16:41
Morgan Stanley Raises Price Target on Sarepta Therapeutics to $135 From $100, Keeps Equalweight Rating
MT Newswires
09/08 10:34
Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2022-2023 Academic Year
Globe Newswire
09/07 08:30
Sarepta Therapeutics Says FDA Lifts Clinical Hold on Trial of Investigational Treatment for Duchenne Muscular Dystrophy
MT Newswires
09/06 09:09
Sarepta Therapeutics to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
Globe Newswire
09/06 08:45
Insider Buy: Sarepta Therapeutics
MT Newswires
08/22 09:52
--RBC Boosts Price Target on Sarepta Therapeutics to $182 From $160, Maintains Outperform Rating
MT Newswires
08/09 07:59
Sarepta Gets Licensing Deal with Broad Institute for MyoAAV Capsids to Treat Rare Genetic Diseases
MT Newswires
08/08 10:57
Sarepta inks licensing deal with Broad Institute for certain adeno-associated viruses
SA Breaking News
08/08 10:06
Sarepta Therapeutics Announces Progress on the MyoAAV Program and Exclusive Licensing Agreement with The Broad Institute for MyoAAV Next-generation Capsids for Rare Genetic Diseases
Globe Newswire
08/08 08:30
--UBS Adjusts Sarepta Therapeutics Price Target to $94 From $87, Maintains Neutral Rating
MT Newswires
08/04 11:15
--Guggenheim Raises Sarepta Therapeutics Price Target to $122 From $100, Maintains Buy Rating
MT Newswires
08/03 10:49
--Oppenheimer Adjusts Sarepta Therapeutics' Price Target to $150 From $125, Maintains Outperform Rating
MT Newswires
08/03 09:36
--RBC Boosts Price Target on Sarepta Therapeutics to $160 From $156, Maintains Outperform Rating
MT Newswires
08/03 08:10
--Berenberg Bank Adjusts Sarepta Therapeutics' Price Target to $98 From $94, Maintains Hold Rating
MT Newswires
08/03 07:16
--Morgan Stanley Boosts Price Target on Sarepta Therapeutics to $100 From $80, Citing Increased Optionality From SRP-9001 Early Filing; Equalweight Kept
MT Newswires
08/03 06:58
Sarepta down after-hours following Q2 bottom line miss, but boosts 2022 revenue guidance
SA Breaking News
08/02 18:09
Sarepta Therapeutics Q2 Loss Narrows as Revenue Increases; Raises Full-Year Sales Guidance
MT Newswires
08/02 17:03
-- Earnings Flash (SRPT) SAREPTA THERAPEUTICS Posts Q2 Loss $-1.18
MT Newswires
08/02 16:13
-- Earnings Flash (SRPT) SAREPTA THERAPEUTICS Reports Q2 Revenue $233.5M
MT Newswires
08/02 16:12
Sarepta Therapeutics Announces Second Quarter 2022 Financial Results and Recent Corporate Developments
Globe Newswire
08/02 16:05
Earnings Reaction History: Sarepta Therapeutics Inc, 50.0% Follow-Through Indicator, 5.0% Sensitive
MT Newswires
08/02 12:28
Notable earnings after Tuesday's close
SA Breaking News
08/01 17:35
--Needham Raises Sarepta Therapeutics' Price Target to $162 From $150, Buy Rating Maintained
MT Newswires
07/29 11:26
Thinking about trading options or stock in Sarepta Therapeutics, Apple, General Electric, Microsoft, or Meta Platforms?
PR Newswire
07/29 09:39
Sector Update: Consumer Stocks Mixed Premarket Friday
MT Newswires
07/29 09:13
Sector Update: Health Care
MT Newswires
07/29 08:53
Sarepta Therapeutics to Submit Biologics License Application for Duchenne Muscular Dystrophy Therapy in Fall
MT Newswires
07/29 08:07
Sarepta Therapeutics Announces Intent to Submit an Accelerated Approval Biologics License Application for its Gene Therapy SRP-9001 to Treat Duchenne Muscular Dystrophy
Globe Newswire
07/29 07:00
Sarepta Therapeutics to Announce Second Quarter 2022 Financial Results and Recent Corporate Developments on August 2, 2022
Globe Newswire
07/26 08:30
--Morgan Stanley Raises Sarepta Therapeutics' Price Target to $80 From $74, Equalweight Rating Kept
MT Newswires
07/15 13:41
--RBC Lifts Price Target on Sarepta Therapeutics to $156 From $155, Maintains Outperform Rating
MT Newswires
07/07 09:09
Sarepta Therapeutics’ Investigational Gene Therapy SRP-9001 for Duchenne Muscular Dystrophy Demonstrates Significant Functional Improvements Across Multiple Studies
Globe Newswire
07/06 08:15
Cantor Fitzgerald Adjusts Sarepta Therapeutics' Price Target to $128 from $140, Keeps Overweight Rating
MT Newswires
06/24 11:03
Credit Suisse Lowers Sarepta Therapeutics' Price Target to $90 from $95 After Muscular Dystrophy Drug Study Put on FDA Hold, Keeps Neutral Rating
MT Newswires
06/24 09:51
Sarepta Therapeutics' Muscular Dystrophy Drug Study Put on FDA Hold; Stock Falls in Late Trading
MT Newswires
06/23 16:49
Sarepta sheds 12% as FDA imposes clinical hold on Duchenne candidate
SA Breaking News
06/23 16:11
Sarepta Therapeutics Provides Update on SRP-5051 for the Treatment of Duchenne Muscular Dystrophy
Globe Newswire
06/23 16:01
Sarepta Therapeutics to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference
Globe Newswire
06/02 08:30
Sarepta Therapeutics grants equity awards to employees
SA Breaking News
06/01 06:20
Goldman Sachs Lowers Sarepta Therapeutics' Price Target to $155 From $181, Buy Rating Kept
MT Newswires
05/24 11:37
Morgan Stanley Adjusts Price Target for Sarepta Therapeutics to $74 From $77, Maintains Equalweight Rating
MT Newswires
05/19 10:36
--RBC Capital Adjusts Sarepta Therapeutics Price Target to $155 From $150, Maintains Outperform Rating
MT Newswires
05/05 10:15
-- Earnings Flash (SRPT) SAREPTA THERAPEUTICS Posts Q1 Loss $-0.56
MT Newswires
05/04 16:51
-- Earnings Flash (SRPT) SAREPTA THERAPEUTICS Reports Q1 Revenue $210.8M, vs. Street Est of $208.2M
MT Newswires
05/04 16:51
Sarepta Therapeutics Announces First Quarter 2022 Financial Results and Recent Corporate Developments
Globe Newswire
05/04 16:05
Earnings Reaction History: Sarepta Therapeutics Inc, 60.0% Follow-Through Indicator, 5.2% Sensitive
MT Newswires
05/04 12:40
Sarepta Therapeutics to Present at the BofA Securities 2022 Healthcare Conference
Globe Newswire
05/04 08:30
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire
04/29 18:23
Sarepta Therapeutics to Announce First Quarter 2022 Financial Results and Recent Corporate Developments on May 4, 2022
Globe Newswire
04/27 08:30
Editas Medicine Appoints Sarepta Therapeutics Executive Gilmore O'Neill as CEO
MT Newswires
04/14 07:44
--Morgan Stanley Adjusts Sarepta Therapeutics Price Target to $77 From $80, Maintains Equal Weight Rating
MT Newswires
04/12 12:52
Goldman screens companies with best and worst pricing power into earnings season
SA Breaking News
04/11 07:48
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire
03/31 18:30
Morgan Stanley projects about a third of biotechs will need financing in 2022
SA Breaking News
03/26 12:00
--Morgan Stanley Adjusts Sarepta Therapeutics Price Target to $80 From $71, Maintains Equalweight Rating
MT Newswires
03/07 11:06
--UBS Adjusts Sarepta Therapeutics Price Target to $87 From $86, Maintains Neutral Rating
MT Newswires
03/03 13:08
Sarepta Therapeutics to Present at Upcoming Investor Conferences
Globe Newswire
03/02 16:30
--RBC Raises Price Target on Sarepta Therapeutics to $150 From $145, Maintains Outperform Rating
MT Newswires
03/02 08:19
Sarepta down 4% after hours despite top and bottom line earnings beats
SA Breaking News
03/01 16:59
Sarepta Therapeutics Q4 Loss Shrinks Amid Higher Revenue
MT Newswires
03/01 16:35
-- Earnings Flash (SRPT) SAREPTA THERAPEUTICS Posts Q4 Revenue $201.5M, vs. Street Est of $198.5M
MT Newswires
03/01 16:15
-- Earnings Flash (SRPT) SAREPTA THERAPEUTICS Reports Q4 Loss $-0.77, vs. Street Est of $-1.14
MT Newswires
03/01 16:15
Sarepta Therapeutics Non-GAAP EPS of -$0.77 beats by $0.37, revenue of $201.46M beats by $2.98M
SA Breaking News
03/01 16:09
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2021 Financial Results and Recent Corporate Developments
Globe Newswire
03/01 16:05
Earnings Reaction History: Sarepta Therapeutics Inc, 60.0% Follow-Through Indicator, 5.2% Sensitive
MT Newswires
03/01 12:29
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2021 Financial Results and Recent Corporate Developments on March 1, 2022
Globe Newswire
02/22 08:30
Morgan Stanley Adjusts Sarepta Therapeutics' Price Target to $71 from $92, Keeps Equalweight Rating
MT Newswires
02/01 10:11
Sarepta Therapeutics, GenEdit Enter Collaboration, Option Deal to Develop Treatments for Neuromuscular Diseases
MT Newswires
02/01 09:28
Sarepta Therapeutics and GenEdit Share Progress on Research Collaboration and Announce Agreement to Develop Gene Editing Therapeutics for Neuromuscular Diseases
Globe Newswire
02/01 08:00
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire
01/31 18:15
Morgan Stanley Adjusts Sarepta Therapeutics Price Target to $92 From $90, Maintains Equalweight Rating
MT Newswires
01/18 13:03
Sarepta Reports Positive Data From Clinical Trial for Duchenne Muscular Dystrophy Treatment Candidate
MT Newswires
01/10 12:06
Sarepta Therapeutics posts prelim. 2021 results below expectations
SA Breaking News
01/10 11:33
Sarepta Therapeutics’ Gene Therapy SRP-9001 Shows Statistically Significant Functional Improvements Compared to Pre-specified Matched External Control in Part 2 of Study SRP-9001-102 for the Treatment of Duchenne Muscular Dystrophy
Globe Newswire
01/10 10:50
Sarepta Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
Globe Newswire
01/06 08:32
Needham Adjusts Sarepta Therapeutics' Price Target to $150 from $157, Keeps Buy Rating
MT Newswires
01/05 11:29
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire
12/31 20:45
Alnylam, Crispr Therapeutics among Goldman's biopharma M&A targets for 2022
SA Breaking News
12/19 09:00
Sarepta raised to Outperform at Oppenheimer; sees a turnaround in 2022
SA Breaking News
12/09 12:39
Oppenheimer Upgrades Sarepta Therapeutics to Outperform From Perform, $125 Price Target
MT Newswires
12/09 10:40
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire
11/30 18:16
Insider Buy: Sarepta Therapeutics
MT Newswires
11/29 14:20
--JPMorgan Upgrades Sarepta Therapeutics to Overweight From Neutral, Boosts Price Target to $130 From $88
MT Newswires
11/05 06:56
--Needham Adjusts Sarepta Therapeutics' Price Target to $157 from $166, Keeps Buy Rating
MT Newswires
11/04 11:47
--Cantor Fitzgerald Adjusts Sarepta Therapeutics' Price Target to $140 From $128, Reiterates Overweight Rating
MT Newswires
11/04 11:47
--Berenberg Bank Adjusts Sarepta Therapeutics PT to $94 From $90, Maintains Hold Rating
MT Newswires
11/04 09:30
--RBC Cuts Price Target on Sarepta Therapeutics to $145 From $148, Maintains Outperform Rating
MT Newswires
11/04 08:13
Sarepta Therapeutics Posts Narrower Q3 Loss, Higher Revenue
MT Newswires
11/04 06:12
-- Earnings Flash (SRPT) SAREPTA THERAPEUTICS Reports Q3 Revenue $189.4M, vs. Street Est of $178.9M
MT Newswires
11/03 16:08
-- Earnings Flash (SRPT) SAREPTA THERAPEUTICS Reports Q3 Loss $-0.19, vs. Street Est of $-1.56
MT Newswires
11/03 16:08
Sarepta Therapeutics Announces Third Quarter 2021 Financial Results and Recent Corporate Developments
Globe Newswire
11/03 16:01
Earnings Reaction History: Sarepta Therapeutics Inc, 70.0% Follow-Through Indicator, 5.6% Sensitive
MT Newswires
11/03 13:01
Sarepta Therapeutics to Announce Third Quarter 2021 Financial Results and Recent Corporate Developments on November 3, 2021
Globe Newswire
10/27 08:30
Credit Suisse Lowers Sarepta Therapeutics' PT to $95 from $100, Updates Model After Secondary Offering, Preliminary Q3 Results; Keeps Neutral Rating
MT Newswires
10/15 08:27
Berenberg Bank Boosts Price Target on Sarepta Therapeutics to $90 From $85, Maintains Hold Rating
MT Newswires
10/15 07:47
Sarepta Therapeutics Prices Public Offering at $81/Share, Expects $500 Million Gross Proceeds
MT Newswires
10/14 03:23
Sarepta Therapeutics Announces Pricing of $500 Million Public Offering of Common Stock
Globe Newswire
10/13 21:15
Hot Stocks: Credit card stocks fall; VMEO jumps; TTM soars on EV valuation; CTSO sets low; SRPT stock offering
SA Breaking News
10/13 17:39
Sector Update: Health Care Stocks Edging Higher Ahead of Wednesday Close
MT Newswires
10/13 15:57
Sarepta Therapeutics Cash Levels Drop From Year-End 2020; Shares Down
MT Newswires
10/13 13:04
CRSP, SRPT and CMRX among after hours movers
SA Breaking News
10/12 17:51
Sarepta Therapeutics Estimates Higher Q3 Product Revenue
MT Newswires
10/12 16:14
Sarepta Therapeutics Starts $500 Million Common Stock Offering
MT Newswires
10/12 16:08
Sarepta Therapeutics Announces Preliminary Financial Results for the Third Quar-ter Ended September 30, 2021
Globe Newswire
10/12 16:04
BTIG Adjusts Sarepta Therapeutics' Price Target to $125 from $110, Keeps Buy Rating
MT Newswires
10/12 10:55
Credit Suisse Lifts Sarepta Therapeutics' PT to $100 from $75, Raises Expectations for SRP-9001 as Ph3 Trial Begins; Keeps Neutral Rating
MT Newswires
10/12 09:27
Sarepta Therapeutics' Muscular Dystrophy Drug Shows Potential in Late-Stage Trial
MT Newswires
10/11 10:42
Sarepta Therapeutics’ SRP-9001 Shows Sustained Functional Improvements in Multiple Studies of Patients with Duchenne
Globe Newswire
10/11 09:13
Codiak BioSciences Says Sarepta Therapeutics Terminates Research License, Option Agreement
MT Newswires
10/08 09:11
Sarepta Therapeutics Opens Genetic Therapies Center of Excellence in Columbus, Ohio
Globe Newswire
10/04 16:30
Sarepta Therapeutics Commences SRP-9001 Study in Duchenne Muscular Dystrophy
MT Newswires
10/04 08:57
Sarepta Therapeutics Announces Initiation of EMBARK, a Global Pivotal Study of SRP-9001, a Gene Therapy for the Treatment of Duchenne Muscular Dystrophy
Globe Newswire
10/04 07:00
Sarepta Therapeutics to Initiate Part B of Study Into Duchenne Muscular Dystrophy Treatment
MT Newswires
09/27 10:36
Sarepta Therapeutics to Initiate Part B of MOMENTUM Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping Following Positive Interactions with FDA
Globe Newswire
09/27 08:30
Guggenheim Upgrades Sarepta Therapeutics to Buy from Neutral, Sets $100 Price Target
MT Newswires
09/15 09:13
Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program
Globe Newswire
09/07 08:30
Takeda in pact with Genevant for nonviral gene therapies targeting rare liver diseases
SA Breaking News
08/23 08:03
--Morgan Stanley Adjusts Price Target on Sarepta Therapeutics to $90 From $93, Maintains Equal-Weight Rating
MT Newswires
08/16 10:17
--Credit Suisse Raises Sarepta Therapeutics' PT to $75 from $72, Keeps Neutral Rating
MT Newswires
08/05 10:53
--RBC Raises Price Target on Sarepta Therapeutics to $148 From $134, Maintains Outperform Rating
MT Newswires
08/05 09:27
--JPMorgan Upgrades Sarepta Therapeutics to Neutral From Underweight, Adjusts Price Target to $87 From $92
MT Newswires
08/05 06:15
-- Earnings Flash (SRPT) SAREPTA THERAPEUTICS Posts Q2 Revenue $164.1M, vs. Street Est of $161.9M
MT Newswires
08/04 16:18
-- Earnings Flash (SRPT) SAREPTA THERAPEUTICS Reports Q2 Loss $-1.52, vs. Street Est of $-1.29
MT Newswires
08/04 16:18
Sarepta Therapeutics Announces Second Quarter 2021 Financial Results and Recent Corporate Developments
Globe Newswire
08/04 16:05
Sarepta Therapeutics Strikes Licensing Deal For Therapy Candidate Calpain 3 to Treat Limb-Girdle Muscular Dystrophy Type 2A
MT Newswires
08/04 15:10
Earnings Reaction History: Sarepta Therapeutics Inc, 72.7% Follow-Through Indicator, 4.8% Sensitive
MT Newswires
08/04 12:21
Sarepta Therapeutics Executes Licensing Agreement for Gene Therapy Program from Nationwide Children’s Hospital to Treat Limb-Girdle Muscular Dystrophy Type 2A
Globe Newswire
08/04 08:30
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire
07/30 17:42
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire
06/30 18:40
After recent weakness, gene therapy space offers a compelling opportunity: BTIG
SA Breaking News
06/15 16:07
BTIG Starts Sarepta Therapeutics at Buy With $110 Price Target
MT Newswires
06/15 07:04
Sarepta Therapeutics to Present at Upcoming Investor Conferences
Globe Newswire
06/03 16:30
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire
05/28 18:55
Sector Update: Health Care Stocks Adding to Small Afternoon Gains
MT Newswires
05/18 16:00
Sector Update: Health Care Stocks Posting Modest Gains
MT Newswires
05/18 13:23
Sarepta keeps momentum as DMD data draw positive views from analysts
SA Breaking News
05/18 12:38
Sarepta Therapeutics' Investigational Gene Therapy SRP-9001 Demonstrates Positive Results
MT Newswires
05/18 10:48
Sarepta posts positive data from SRP-9001 DMD study
SA Breaking News
05/18 09:08
Sarepta Therapeutics’ Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy, SRP-9001, Demonstrates Robust Expression and Consistent Safety Profile Using Sarepta’s Commercial Process Material
Globe Newswire
05/18 08:50
Sarepta Therapeutics to Share Expression and Safety Results from Study 103 (ENDEAVOR) Evaluating SRP-9001, its Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy
Globe Newswire
05/17 16:05
Cramer is calling them 'WoodStocks'; latest changes to ARK ETFs
SA Breaking News
05/13 02:59
-- Earnings Flash (SRPT) SAREPTA THERAPEUTICS Posts Q1 Revenue $146.9M, vs. Street Est of $143.1M
MT Newswires
05/05 16:21
-- Earnings Flash (SRPT) SAREPTA THERAPEUTICS Posts Q1 Loss $-1.54, vs. Street Est of $-1.57
MT Newswires
05/05 16:21
Sarepta Therapeutics Announces First Quarter 2021 Financial Results and Recent Corporate Developments
Globe Newswire
05/05 16:05
Earnings Reaction History: Sarepta Therapeutics Inc, 80.0% Follow-Through Indicator, 5.0% Sensitive
MT Newswires
05/05 12:46
Sarepta Therapeutics to Present at Upcoming Investor Conferences
Globe Newswire
05/04 16:30
Sarepta Therapeutics Reports Phase 2 Results for SRP-5051 to Treat Duchenne Muscular Dystrophy
MT Newswires
05/03 09:22
Sarepta releases positive data on muscular dystrophy drug, but with safety concern
SA Breaking News
05/03 09:19
Sarepta Therapeutics Reports Positive Clinical Results from Phase 2 MOMENTUM Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51
Globe Newswire
05/03 08:50
MIMEDX Files Definitive Proxy Materials and Mails Letter to Shareholders Highlighting Actions Taken to Transform MIMEDX and Drive Significant Value for Shareholders
Globe Newswire
05/03 08:02
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire
04/30 18:45
Sarepta Therapeutics to Release Trial Data for Prospective Duchenne Muscular Dystrophy Therapy
MT Newswires
04/30 16:38
Sarepta Therapeutics to Share Clinical Update for 30 mg/kg arm of MOMENTUM Study for SRP-5051, Its Investigational PPMO for the Treatment of Duchenne Muscular Dystrophy
Globe Newswire
04/30 16:05
Sarepta Therapeutics to Announce First Quarter 2021 Financial Results and Recent Corporate Developments on May 5, 2021
Globe Newswire
04/28 08:30
Sarepta recommends stockholders reject TRC capital's mini tender offer
SA Breaking News
04/26 16:52
Sarepta Recommends Stockholders Reject the Below-Market Mini-Tender Offer by TRC Capital Investment Corporation
Globe Newswire
04/26 16:05
Homology Medicines promotes Tim Kelly to COO
SA Breaking News
04/12 08:56
Sarepta Therapeutics Announces Fourth Year of Route 79, The Duchenne Scholarship Program
Globe Newswire
03/23 08:30
Sarepta’s latest muscular dystrophy trial results viewed favorably at Baird
SA Breaking News
03/19 16:15
SRPT, UPST, MRKR and ALPN among after-hours movers
SA Breaking News
03/18 17:42
Sarepta posts new results from SRP-9003 muscular dystrophy study
SA Breaking News
03/18 16:51
Sarepta Therapeutics’ Investigational Gene Therapy SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E Shows Sustained Expression and Functional Improvements 2 Years After Administration
Globe Newswire
03/18 16:31
Sarepta Therapeutics to Present Results from its Gene Therapy and RNA Platforms at the 2021 Annual MDA Clinical and Scientific Conference
Globe Newswire
03/15 08:30
Analyst Actions: RBC Capital Adjusts Sarepta Therapeutics PT to $133 From $132, Maintains Outperform Rating
MT Newswires
03/12 09:14
--Analyst Actions: RBC Capital Adjusts Sarepta Therapeutics' Price Target to $132 From $143, Maintains Outperform Rating
MT Newswires
03/02 08:36
Sarepta slides on revenue miss
SA Breaking News
03/01 16:47
Sarepta Therapeutics Posts Wider Q4 Net Loss, Revenue Rises
MT Newswires
03/01 16:26
-- Earnings Flash (SRPT) SAREPTA THERAPEUTICS Posts Q4 Revenue $145.1M, vs. Street Est of $145.5M
MT Newswires
03/01 16:07
-- Earnings Flash (SRPT) SAREPTA THERAPEUTICS Posts Q4 EPS $-1.84, vs. Street Est of $-1.46
MT Newswires
03/01 16:07
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2020 Financial Results and Recent Corporate Developments
Globe Newswire
03/01 16:05
Notable earnings after Monday's close
SA Breaking News
02/28 17:35
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire
02/26 19:12
Sarepta Wins FDA Approval for Amondys 45 for Rare Form of Duchenne Muscular Dystrophy
MT Newswires
02/25 15:53
Sarepta shares up as FDA approves AMONDYS 45 for Duchenne Muscular Dystrophy
SA Breaking News
02/25 14:27
Sarepta Therapeutics Announces FDA Approval of AMONDYS 45™ (casimersen) Injection for the Treatment of Duchenne Muscular Dystrophy (DMD) in Patients Amenable to Skipping Exon 45
Globe Newswire
02/25 14:10
Sarepta Therapeutics to Present at Upcoming Investor Conferences
Globe Newswire
02/24 16:30
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2020 Financial Results and Recent Corporate Developments on March 1, 2021
Globe Newswire
02/22 08:30
Seeking Alpha Catalyst Watch
SA Breaking News
02/19 15:15
REGENXBIO patent case may weigh on Sarepta, according to Morgan Stanley
SA Breaking News
02/09 14:34
Sarepta Therapeutics Announces Winners of the “Rare Lessons” Lesson Planning Competition
Globe Newswire
02/04 16:30
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Sarepta Therapeutics, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm
PR Newswire
02/01 17:16
Sarepta provides inducement grants to 26 employees hired in January
SA Breaking News
01/30 16:00
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire
01/29 20:30
Sarepta Therapeutics, Genevant Sciences Unveil Research Collaboration for Neuromuscular Diseases
MT Newswires
01/13 11:29
Sarepta and Genevant Sciences strike research collaboration deal
SA Breaking News
01/13 08:43
Sarepta Therapeutics and Genevant Sciences Announce Research Collaboration for Lipid Nanoparticle-Based Gene Editing Therapeutics
Globe Newswire
01/13 08:30
Sarepta Therapeutics, Inc. Investors: Company Investigated by the Portnoy Law Firm
Globe Newswire
01/12 13:30
Analyst Actions: Citigroup Downgrades Sarepta Therapeutics to Neutral from Buy, Sets $108 Price Target
MT Newswires
01/12 10:02
Sarepta cut to neutral at Citi after DMD gene therapy trial failure
SA Breaking News
01/12 06:56
SHAREHOLDER ALERT: Barr Law Group Investigating the Officers and Directors of SRPT, PS, RP, and PGZ; Shareholders are Encouraged to Contact the Firm
Globe Newswire
01/12 06:00
Analyst Actions: UBS Cuts Sarepta Therapeutics to Neutral From Buy, PT to $87 From $212 on Duchenne Muscular Dystrophy Treatment Study Results
MT Newswires
01/11 08:42
SRPT EQUITY ALERT: ROSEN, GLOBAL INVESTOR COUNSEL, Announces Investigation of Securities Claims Against Sarepta Therapeutics, Inc.; Encourages Investors with Losses Exceeding $1 Million to Contact Firm - SRPT
PR Newswire
01/09 13:15
SRPT INVESTIGATION ALERT: Bernstein Liebhard is Investigating Sarepta Therapeutics, Inc. For Violations of the Securities Laws
PR Newswire
01/08 18:48
After Hours Watch List Scorecard: MRUS, WDFC, SRPT
MT Newswires
01/08 16:35
Sarepta price target cut in half at Baird after gene therapy setback
SA Breaking News
01/08 16:03